You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表现》永泰生物-B(06978.HK)收15.48元高上市价41% 每手账面赚4,480元
阿思达克 07-10 16:46
永泰生物-B(06978.HK)首日挂牌,股价高开近22%报13.4元,高低见16.86元/13.32元,全日收15.48元,较上市价11元,高4.48元或近41%,成交7,362万股,涉资10.99亿元。不计手续费,每手1,000股,账面赚4,480元。

永泰是内地一家领先细胞免疫治疗生物医药公司,13年来专注於T细胞免疫治疗研发和商业化,公司核心在研产品EAL是内地首款获准进入II期临床试验细胞免疫产品及当下唯一获准进入实体瘤治疗II期临床试验细胞免疫产品,该药属多靶点肿瘤细胞免疫治疗产品,并对多种癌症显示出治疗效果。

永泰是次来港上市共发售1亿股,并已引入4名基石投资者合共认购2,810.9万股;其中10%公开发售获逾258倍超购,已启动回拨机制占比增至50%,认购一手中签率20%;股份以招股范围(10.5-11元)上限定价,料集资净额约10.24亿元,主要用作投资EAL正在进行临床试验和商业化及扩大EAL临床适应症(不包括肝癌)、用於投资CAR-T-19及TCR-T系列在研产品临床试验、用於投资公司产品管线中其他在研产品开发等。上市联席保荐人建银国际及国信证券。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account